EP2099819A4 - Multimeric fc receptor polypeptides including a modified fc domain - Google Patents

Multimeric fc receptor polypeptides including a modified fc domain

Info

Publication number
EP2099819A4
EP2099819A4 EP07845376A EP07845376A EP2099819A4 EP 2099819 A4 EP2099819 A4 EP 2099819A4 EP 07845376 A EP07845376 A EP 07845376A EP 07845376 A EP07845376 A EP 07845376A EP 2099819 A4 EP2099819 A4 EP 2099819A4
Authority
EP
European Patent Office
Prior art keywords
multimeric
domain
modified
receptor polypeptides
polypeptides including
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07845376A
Other languages
German (de)
French (fr)
Other versions
EP2099819A1 (en
Inventor
Phillip Mark Hogarth
Bruce David Wines
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suppremol GmbH
Original Assignee
Suppremol GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/AU2006/001890 external-priority patent/WO2007068047A1/en
Priority claimed from US11/762,664 external-priority patent/US8354109B2/en
Application filed by Suppremol GmbH filed Critical Suppremol GmbH
Publication of EP2099819A1 publication Critical patent/EP2099819A1/en
Publication of EP2099819A4 publication Critical patent/EP2099819A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP07845376A 2006-12-13 2007-12-13 Multimeric fc receptor polypeptides including a modified fc domain Withdrawn EP2099819A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/AU2006/001890 WO2007068047A1 (en) 2005-12-13 2006-12-13 Multimeric fc receptor polypeptides
US11/762,664 US8354109B2 (en) 2005-12-13 2007-06-13 Multimeric Fc receptor polypeptides
PCT/AU2007/001934 WO2008070927A1 (en) 2006-12-13 2007-12-13 Multimeric fc receptor polypeptides including a modified fc domain

Publications (2)

Publication Number Publication Date
EP2099819A1 EP2099819A1 (en) 2009-09-16
EP2099819A4 true EP2099819A4 (en) 2010-03-17

Family

ID=40961582

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07845376A Withdrawn EP2099819A4 (en) 2006-12-13 2007-12-13 Multimeric fc receptor polypeptides including a modified fc domain

Country Status (6)

Country Link
EP (1) EP2099819A4 (en)
JP (1) JP2010512154A (en)
BR (1) BRPI0721078A2 (en)
CA (1) CA2671732A1 (en)
RU (1) RU2009126545A (en)
WO (1) WO2008070927A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102718836B (en) * 2009-04-24 2014-04-16 上海交通大学医学院附属瑞金医院 Short peptide, immune inhibitor containing the same and application thereof
EP2492689B8 (en) * 2011-02-22 2013-12-25 Bernhard-Nocht-Institut für Tropenmedizin Detection of antibodies using an improved immune complex (IC) ELISA
CN103911387A (en) * 2013-01-08 2014-07-09 深圳先进技术研究院 Eukaryotic expression vector containing mouse IgG2a Fc label, and its construction method
KR101685532B1 (en) * 2016-04-26 2016-12-13 한국프라임제약주식회사 A VEGFR fusion protein
WO2022252131A1 (en) * 2021-06-01 2022-12-08 Virogin Biotech Canada Ltd. Multivalent recombinant ace2 and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010202A1 (en) * 2001-07-26 2003-02-06 Medexgen Co. Ltd. Concatameric immunoadhesion

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2272533A1 (en) * 2003-01-13 2011-01-12 MacroGenics, Inc. Soluble FcyR fusion proteins and methods of use thereof
EP1718672A4 (en) * 2004-02-10 2009-11-25 Austin Research Inst Crystal structures and models for fc receptors and uses thereof in the design or identification of fc receptor modulator compounds
WO2007068047A1 (en) * 2005-12-13 2007-06-21 Trillium Therapeutics Inc Multimeric fc receptor polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010202A1 (en) * 2001-07-26 2003-02-06 Medexgen Co. Ltd. Concatameric immunoadhesion

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IERINO F L ET AL: "RECOMBINANT SOLUBLE HUMAN FCGAMMARII: PRODUCTION, CHARACTERIZATION AND INHIBITION OF THE ARTHUS REACTION", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, UNITED STATES, vol. 178, no. 5, 1 November 1993 (1993-11-01), pages 1617 - 1628, XP009015491, ISSN: 0022-1007 *
KURUCZ ISTVAN ET AL: "Bacterially expressed human FcgammaRIIb is soluble and functionally active after in vitro refolding", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 75, no. 1, 1 December 2000 (2000-12-01), pages 33 - 40, XP002511480, ISSN: 0165-2478 *
POWELL M S ET AL: "Investigation of FcgammaRIIa dimerization", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 14, no. 6, 20 April 2000 (2000-04-20), pages A960, XP009111142, ISSN: 0892-6638 *
See also references of WO2008070927A1 *

Also Published As

Publication number Publication date
BRPI0721078A2 (en) 2014-10-07
JP2010512154A (en) 2010-04-22
RU2009126545A (en) 2011-01-20
WO2008070927A1 (en) 2008-06-19
EP2099819A1 (en) 2009-09-16
CA2671732A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
IL248322A0 (en) Variant activin receptor polypeptides and uses thereof
IL248128A0 (en) Stabilized receptor polypeptides and uses thereof
GB2437827B (en) Touch screen element
IL196056A0 (en) Il-8 receptor antagonists
ZA200808358B (en) IL-8 receptor antagonists
GB0721686D0 (en) Polypeptides
ATE467622T1 (en) PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS CB2 RECEPTOR MODULATORS
IL202107A0 (en) Fc RECEPTOR BINDING POLYPEPTIDES AND USES THEREOF
IL198990A0 (en) Cb1 receptor modulators
IL194700A0 (en) Il-8 receptor antagonists
EP2099300A4 (en) Il-8 receptor antagonists
GB0701992D0 (en) Grehlin Receptor Modulators
IL192693A0 (en) Urotensin ii receptor antagonists
IL205749A0 (en) Modified il-4 mutein receptor antagonists
EP2099819A4 (en) Multimeric fc receptor polypeptides including a modified fc domain
HK1137353A1 (en) Urotensin ii receptor antagonists ii
GB0623539D0 (en) Polypeptides
ZA200806237B (en) Cannibinoid receptor modulators
GB0712302D0 (en) Chrondroitinase polypeptides
EP2032789A4 (en) Height-adjustable hinge
GB0705829D0 (en) Waste receptor
ZA200904663B (en) CB1 receptor modulators
GB0604684D0 (en) Receptor
GB0608516D0 (en) Receptor
GB0623399D0 (en) Receptor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090625

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20100215

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20100601

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101214